Molecular biology of gastric cancer

Clinical and Translational Oncology

Volumn 9, Issue 4, 2007, Pages 208-215

  Cervantes, Andres ^a   Rodriguez Braun E ^a   Perez Fidalgo A ^a   Chirivella Gonzalez I ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Angiogenesis; Gastric cancer; Genetic alterations; Molecular markers

Indexed keywords

ALPHA CATENIN; ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; APC PROTEIN; BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FRAGILE HISTIDINE TRIAD PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; HERMES ANTIGEN; MEMBRANE RECEPTOR; PLAKOGLOBIN; PLATELET DERIVED GROWTH FACTOR A; PROTEIN MLH1; PROTEIN P53; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR RUNX3; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA2; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 3; WNT PROTEIN; TUMOR MARKER;

BONE MARROW CELL; CPG ISLAND; DRUG TARGETING; EPIGENETICS; GASTRECTOMY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MICROSATELLITE INSTABILITY; MOLECULAR BIOLOGY; NONHUMAN; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH CARCINOGENESIS; ADULT; AGED; CELL ADHESION; COMPARATIVE STUDY; GENETIC MARKER; GENETICS; MALE; METABOLISM; MORTALITY; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROTO ONCOGENE; STOMACH; STOMACH TUMOR; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CELL ADHESION; GASTRECTOMY; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; HUMANS; MALE; MICROSATELLITE INSTABILITY; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENES; SIGNAL TRANSDUCTION; STOMACH; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34447102329     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0041-4     Document Type: Review

References (46)

1. Yao JC, Crane CH, Mansfield PF (2006) Carcinoma of the stomach. In: Holland JF, Frei E (eds) Cancer medicine 7. BC Decker INC, Hamilton, London, pp 1268-1317
2. Houghton JM, Stoicov C, Nomura S et al (2004) Gastric cancer originating from bone marrowderived cells. Science 306:1568-1571
3. Endoh H, Tamura G, Ajioka Y et al (2000) Frequent hypermethylation of the hMLH1gene promoter in differentiated-type tumor of the stomach with the gastric foveolar phenotype. Am J Pathol 157:717-722
4. Bevilacqua RA, Simpsom AJ (2000) Methylation of the hMLH1 promoter but no hMLH1 mutations in sporadic gastric cancer. Int J Cancer 87:200-203
5. Tamura G, Yin J, Wang S et al (2000) E-cadherin gene promoter hypermethylation in primary human gastric carcinoma. J Natl Cancer Inst 92: 569-573
6. Sato K, Tamura G, Tsuchiya T et al (2001) Frequent loss of expression without sequence mutation of the DCC gene in primary gastric cancer. Br J Cancer 85:199-203
7. Jang TJ, Kim DI, Shim YM et al (2001) p16INK4a promoter hypermethylation of nontumorous tissue adjacent to gastric cancer is correlated with glandular atrophy and chronic inflammation. Int J Cancer 93:629-634
8. Li QL, Ito K, Sakakura C et al (2002) Casual relationship between the loss of RUNX3 expression and gastric cancer. Cell 109:113-124
9. Chong KM, Fukayama M, Hayashi Y et al (1994) Microsatellite instability in the progression of gastric carcinoma. Cancer Res 54:4595-4597
10. Semba S, Yokozaki H, Yamamoto S et al (1996) Microsatellite instability in precancerous lesions and adenocarcinomas of the stomach. Cancer 77[8Suppl]:1620-1627
11. Ottini L, Palli D, Falchetti M et al (1997) Microsatellite instability in gastric cancer is associated with tumor location and family history in a high risk population from Tuscany. Cancer Res 57: 4523-4529
12. Myeroff LL, Parsons R, Kim SJ et al (1995) A transforming growth factor beta receptor type II gene mutations common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 55:5545-5547
13. Guo RJ, Arai H, Kitayama Y et al (2001) Microsatellite instability of papillary subtype of human gastric adenocarcinoma and hMLH1 promoter hypermethylation in the surrounding mucosa. Pathol Int 51:240-247
14. Kim GP, Colangelo LH, Wieand HS et al (2007) Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 25:767-772
15. Boland CR (2007) Clinical uses of microsatellite instability testing in colorectal cancer: An ongoing challenge. J Clin Oncol 25:754-756
16. Rhyu MG, Park WS, Yung YJ et al (1994) Allelic deletions of MCC/APC and p53 are frequent late events in human gastric carcinogenesis. Gastroenterology 106:1584-1588
17. Wu MS, Shun CT, Wang HP et al (1997) Genetic alterations in gastric cancer: Relation to histological subtypes, tumor stage and Helicobacter pylori infection. Gastroenterology 112:1457-1465
18. Brito MJ, Williams GT, Thompson H, Filipe MI (1994) Expression of p53 in early (T1) gastric carcinoma and precancerous adjacent mucosa. Gut 35:1697-1700
19. Ohmiya N, Taguchi A, Mabuchi N et al (2006) MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric adenocarcinoma and poor prognosis. J Clin Oncol 24:4434-4440
20. Horii A, Nakatsuru S, Miyoshi Y et al (1992) The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res 52:3231-3233
21. Hsieh LL, Huang YC (1995) Loss of heterozygosity of APC/MCC gene in differentiated and undifferentiated gastric carcinomas in Taiwan. Cancer Lett 96:169-174
22. Fang DC, Jass JR, Wang DX (1998) Loss of heterozygosity and loss of expression of the DCC gene in gastric cancer. J Clin Pathol 51:593-596
23. Graziano F, Cascinu S, Staccioli MP et al (2001) Potential role and chronology of abnormal expression of the deleted in colon cancer (DCC) and p53 proteins in the development of gastric cancer. BMC Cancer 1:9
24. Baffa R, Veronese ML, Santoro R et al (1998) Loss of FHTI expression in gastric carcinoma. Cancer Res 58:4708-4714
25. Capucci D, Santoro E, Hauck WW et al (2000) FHTI expression in gastric adenocarcinoma: Correlation with disease stage and survival. Cancer 88:24-34
26. Huiping C, Kristjandottir S, Bergthorson JT et al (2002) High frequency of LOH, MSI, and abnormal expression of FHIT in gastric cancer. Eur J Cancer 38:728-735
27. Hirohashi S (1998) Inactivation of the E-cadherin- mediated cell adhesion system in human cancers. Am J Pathol 153:333-339
28. Jawhari A, Jordan S, Poole S et al (1997) Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: Relationship with patient survival. Gastroenterology 112:46-54
29. Keller G, Vogelsang H, Becker I et al (1999) Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an Ecadherin germline mutation. Am J Pathol 155:337-342
30. Suriano G, Mulholland, de Wever O et al (2003) The intracellular E-cadherine germline mutation V832 lacks the ability to mediate cell-cell adhesion and to suppress invasion. Oncogene 22: 5716-5719
31. Ebert MP, Fei G, Kahmann S et al (2002) Increased beta-catenin mRNA levels and mutational alterations of the APC and beta-catenin gene are present in intestinal-type gastric cancer. Carcinogenesis 23:87-91
32. Ebert MO, Yu J, Hoffmann J et al (2003) Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol 21:1708-1714
33. Sato S, Yokozaki H, Yasui W et al (1999) Silencing of the CD44 gene by CpG methylation in a human gastric carcinoma cell line. Jpn J Cancer Res 90:485-489
34. Yoo CH, Noh SH, Kim H et al (1999) Prognostic significance of CD44 and Mn23 expression in patients with stage II and IIIA gastric adenocarcinoma. J Surg Oncol 71:22-28
35. Yamaguchi A, Goi T, Yu J et al (2002) Expression of CD44v6 in advanced gastric cancer and its relationship with hematogenous metastasis and long term prognosis. J Surg Oncol 79:230-235
36. Slesak B, Harlozinska A, Porebska I et al (1998) Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB2 and c-erbB3) in gastric cancer and chronic gastritis. Anticancer Res 18:2727-2732
37. Kuwahara A, Katano M, Nakamura M et al (1999) New therapeutic strategy for gastric carcinoma: A two step evaluation of malignant potential from its molecular biology and pathological characteristics. J Surg Oncol 72:141-144
38. Katano M, Nakamura M, Fujimoto K et al (1998) Prognostic value of platelet-derived growth factor-A (PDGF-A) in gastric carcinoma. Ann Surg 227:365-371
39. Huang TJ, Wang JY, Lin SR et al (2001) Overexpression of the c-met protooncogene in human gastric carcinoma - a correlation to clinical features. Acta Oncol 40:638-641
40. Maeda K, Kang SM, Onoda N et al (1999) Vascular endothelial growth factor expression in preoperative biopsies specimens correlate with disease recurrence in patients with early gastric carcinoma. Cancer 86:566-571
41. Maehara Y, Kabashima A, Koga T et al (2000) Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery 128:408-416
42. Yoshikawa T, Tsuburaya A, Kobayashi O et al (2000) Plasma concentration of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 153:7-12
43. Jüttner S, Wibmann C, Jons T et al (2006) Vascular endothelial growth factor-D and its receptor VEGF-3: Two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 24:228-240
44. Anzai H, Kitadai Y, Bucana CD et al (1998) Expression of metastasis-related genes in surgical specimens of human gastric cancer can predict disease recurrence. Eur J Cancer 34:556-565
45. Yao JC, Wang L, Wei D et al (2004) Association between expression of transcription factor SP1 and increased vascular endothelial growth factor expression, advanced stage and poor survival in patients with resected gastric cancer. Clin Cancer Res 10:4109-4117
46. Shah MA (2006) Gastric cancer: An update. Current Oncol Rep 8:183-191